|
1.
|
McClain CJ, Kasarskis EJ and Allen JJ:
Functional consequences of zinc deficiency. Prog Food Nutr Sci.
9:185–226. 1985.PubMed/NCBI
|
|
2.
|
McClain CJ, Marsano L, Burk RF and Bacon
B: Trace metals in liver disease. Semin Liver Dis. 11:321–339.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Prasad AS: Zinc and immunity. Mol Cell
Biochem. 188:63–69. 1998. View Article : Google Scholar
|
|
4.
|
Powell SR: The antioxidant properties of
zinc. J Nutr. 130:S1447–S1454. 2000.
|
|
5.
|
Vallee BL, Wacker WEC, Bartholomay AF,
Robin ED, Vallee RL and Wacker WE: Zinc metabolism in hepatic
dysfunction. I Serum zinc concentrations in Laennëc’s cirrhosis and
their validation by sequential analysis. N Engl J Med. 255:403–408.
1956.
|
|
6.
|
Bode JC, Hanisch P, Henning H, Koenig W,
Richter FW and Bode C: Hepatic zinc content in patients with
chronic active and chronic persistent hepatitis. Hepatology.
8:1650–1659. 1988.PubMed/NCBI
|
|
7.
|
Moriyama M, Matsumura H, Fukushima A, et
al: Clinical significance of evaluation of serum zinc
concentrations in C-viral chronic liver disease. Dig Dis Sci.
51:1967–1977. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Stamoulis I and Kouraklis G: Zinc and
liver: an active interaction. Dig Dis Sci. 52:1595–1612. 2007.
View Article : Google Scholar
|
|
9.
|
Riggio O, Merli M, Capocaccia L, et al:
Zinc supplementation reduces blood ammonia and increases liver
ornithine transcarbamylase activity in experimental cirrhosis.
Hepatology. 16:785–789. 1992. View Article : Google Scholar
|
|
10.
|
Gimenez A, Pares A, Alie S, et al:
Fibrogenic and collagenolytic activity in
carbon-tetrachloride-injured rats: beneficial effects of zinc
administration. J Hepatol. 21:292–298. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Himoto T, Hosomi N, Nakai S, et al:
Efficacy of zinc administration in patients with hepatitis C
virus-related chronic liver disease. Scand J Gastroenterol.
42:1078–1087. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Fartoux L, Poujol-Robert A, Guechot J,
Wendum D, Poupon R and Serfaty L: Insulin resistance is a cause of
steatosis and fibrosis progression in chronic hepatitis C. Gut.
254:1003–1008. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Mirandola S, Realdon S, Iqbal J, et al:
Liver microsomal triglyceride transfer protein is involved in
hepatitis C liver steatosis. Gastroenterology. 130:1661–1669. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Aytug S, Reich D, Sapiro LE, Berstein D
and Begum N: Impaired IRS-1/PI3-kinase signaling in patients with
HCV: a mechanism for increased prevalence of type diabetes.
Hepatology. 38:1384–1392. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Maeno T, Okumura A, Ishikawa T, et al:
Mechanisms of increased insulin resistance in non-cirrhotic
patients with chronic hepatitis C virus infection. J Gastroenterol
Hepatol. 18:1358–1363. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Camma C, Bruno S, Di Marco V, et al:
Insulin resistance is associated with steatosis in nondiabetic
patients with genotype 1 chronic hepatitis C. Hepatology. 43:64–71.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Moucari R, Asselah T, Cazals-Hatem D, et
al: Insulin resistance in chronic hepatitis C: association with
genotypes 1 and 4, serum HCV-RNA levels and liver fibrosis.
Gastroenterology. 134:416–423. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Hui JM, Sud A, Farrell GC, et al: Insulin
resistance is associated with chronic hepatitis C and virus
infection fibrosis progression. Gastroenterology. 125:1695–1704.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Furutani M, Nakashima T, Hirohama A, et
al: Insulin resistance/β cell function and serum ferritin level in
non-diabetic patients with hepatitis C virus infection. Liver Int.
23:294–299. 2003.
|
|
20.
|
Chausmer AB: Zinc, insulin and diabetes. J
Am Coll Nutr. 17:109–115. 1998. View Article : Google Scholar
|
|
21.
|
Kinlaw WB, Levine AS, Morley JE, Silvis SE
and McClain CJ: Abnormal zinc metabolism in type II diabetes
mellitus. Am J Med. 75:273–277. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Adachi Y, Yoshida J, Kodera Y, et al: Oral
administration of a zinc complex improves type 2 diabetes and
metabolic syndrome. Biochem Biophys Res Commun. 351:165–170. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Mattews DR, Hosker JP, Rudenski AS, Naylor
BA, Trecher DF and Turner RC: Homeostasis model assessment: insulin
resistance and beta-cell function from fasting plasma glucose and
insulin concentration in man. Diabetologia. 28:412–429. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Lifschitz MD and Henkin RI: Circadian
variation in copper and zinc in man. J Appl Physiol. 31:88–92.
1971.PubMed/NCBI
|
|
25.
|
Lau JY, Davis GL, Kniffen J, et al:
Significance of serum hepatitis C virus RNA levels in chronic
hepatitis C. Lancet. 341:1501–1504. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Simmonds P, Alberti A, Alter HJ, et al: A
proposed system for the nomenclature of hepatitis C viral
genotypes. Hepatology. 19:1321–1324. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Ichida F, Tsuji T, Omata M, et al: New
Inuyama classification: new criteria for histological assessment of
chronic hepatitis. Int Hepatol Commun. 6:112–119. 1996. View Article : Google Scholar
|
|
28.
|
Brunt EM, Janney CG, Di Bisceglie AM,
Neuschwander-Tetri BA and Bacon BR: Nonalcoholic steatohepatitis: a
proposal for grading and staging the histological lesions. Am J
Gastroenterol. 94:2467–2474. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Okuda M, Li K, Beard MR, Showalter LA,
Scholle F, Lemon SM and Weinman SA: Mitochondrial injury, oxidative
stress and antioxidant gene expression are induced by hepatitis C
virus core protein. Gastroenterology. 122:366–375. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Hayashi H, Takikawa T, Nishimura N, Yano
M, Isomura T and Sakamoto N: Improvement of serum aminotransferase
levels after phlebotomy in patients with chronic active hepatitis
C. Am J Gastroenterol. 89:986–989. 1994.PubMed/NCBI
|
|
31.
|
Koike K and Miyoshi H: Oxidative stress
and hepatitis C viral infection. Hepatol Res. 34:65–73. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Fujita N, Horiike S, Sugimoto R, et al:
Hepatic oxidative DNA damage correlates with iron overload in
chronic hepatitis C patients. Free Radic Biol Med. 42:352–362.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
De Sanctis V, Gamberini MR, Borgatti L,
Atti G, Vullo C and Bagni B: Alpha and beta cell evaluation in
patients with thalassaemia intermedia and iron overload. Postgrad
Med J. 61:963–967. 1985.PubMed/NCBI
|
|
34.
|
Dehshal MH, Hooghooghi AH, Kebrayaeezadeh
A, et al: Zinc deficiency aggravates abnormal glucose metabolism in
thalassemia major patients. Med Sci Monit. 13:CR235–239.
2007.PubMed/NCBI
|
|
35.
|
Miura K, Taura K, Kodama Y, Schnabl B and
Brenner DA: Hepatitis C virus-induced oxidative stress suppresses
hepcidin expression through increased histone deacetylase activity.
Hepatology. 48:1420–1429. 2008. View Article : Google Scholar
|
|
36.
|
Mifuji R, Kobayashi Y, Ma N, et al: Role
of transferrin receptor 2 in hepatic accumulation of iron in
patients with chronic hepatitis C. J Gastroenterol Hepatol.
21:144–151. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Fernandez-Real JM, Lopez-Bermejo A and
Ricart W: Cross-talk between iron metabolism and diabetes.
Diabetes. 51:2348–2354. 2002. View Article : Google Scholar : PubMed/NCBI
|
